摘要
目的探讨Bcl-2、C-erbB2和PCNA作为浸润性乳腺癌新辅助治疗预后指标的可行性。方法选择55例接受新辅助治疗的乳腺癌病例，空芯针穿刺标本及化疗后根治标本分别行S-P法免疫组织化学染色。所有病例均接受3—4周期含蒽环类化疗药的联合化疗，肿瘤缩小率用彩色多谱勒超声评估。结果术前化疗有效率（CR＋PR）为61．8％（34／55），完全缓解率（CR）为9．1％（5／55）。C-erbB2在分化较差、受体阴性病例中高表达（P〈0．05）。CerbB2阴性病例肿瘤缩小明显，与C—erbB2表达阳性病例相比，差异有显著性（P〈0．01）。PCNA在组织学高分级肿瘤中表达增高（P〈0．05），化疗后PCNA表达减弱。Bcl-2表达在化疗前后及与各临床病理因素间比较中差异无显著性（P〉0．05）。结论C-erbB2与PCNA可作为预测乳腺癌化疗疗效的有价值的指标。
Objective To evaluate the feasibility of Bcl-2,CerbB2 and PCNA as prognostic indicators for neoadjuvant chemotherapy in invasive breast cancer. Methods Fifty-five patients underwent core needle biopsy before neoadjuvant chemotherapy. S-P immunohistochemical staining was used to detect the expression of Bcl-2, CerbB2 and PCNA in both biopsy and operation specimens. All patients received three to four courses of anthracycline-based chemotherapy. Tumor reduction rate was assessed by color ultrasound. Results The effective rate（ CR ＋ PR）for neoadjuvant chemotherapy was 61.8 % （34/55）, complete remission rate（CR） was 9.1% （5/55）. CerbB2 was overexpressed in patients with poor differentiation and estrogen receptors negative（P 〈 0.05）. Tumor was decreased in size significantly in patients with CerbB2 negative expression as compared with that in patients with positive expression（P 〈0.01 ）. The expression of PCNA was increased in patients with high histological grade （P 〈 0. 05 ） and its expression was decreased after chemotherapy. Bcl-2 expression did not have remarkable changes after chemotherapy （ P 〉 0.05 ）. Conclusions CerbB2 and PCNA might be valuable factors in predicting chemotherapy efficacy in breast cancer.
出处
《中国肿瘤临床与康复》
2007年第1期8-10,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
